These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26553684)

  • 1. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
    Diallo A; Sow SO; Idoko OT; Hirve S; Findlow H; Preziosi MP; Elie C; Kulkarni PS; Parulekar V; Diarra B; Cheick Haidara F; Diallo F; Tapia M; Akinsola AK; Adegbola RA; Bavdekar A; Juvekar S; Chaumont J; Martellet L; Marchetti E; LaForce MF; Plikaytis BD; Enwere GC; Tang Y; Borrow R; Carlone G; Viviani S
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S521-30. PubMed ID: 26553684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.
    Sow SO; Okoko BJ; Diallo A; Viviani S; Borrow R; Carlone G; Tapia M; Akinsola AK; Arduin P; Findlow H; Elie C; Haidara FC; Adegbola RA; Diop D; Parulekar V; Chaumont J; Martellet L; Diallo F; Idoko OT; Tang Y; Plikaytis BD; Kulkarni PS; Marchetti E; LaForce FM; Preziosi MP
    N Engl J Med; 2011 Jun; 364(24):2293-304. PubMed ID: 21675889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.
    Price GA; Hollander AM; Plikaytis BD; Mocca BT; Carlone G; Findlow H; Borrow R; Sow SO; Diallo A; Idoko OT; Enwere GC; Elie C; Preziosi MP; Kulkarni PS; Bash MC
    Clin Infect Dis; 2015 Nov; 61 Suppl 5():S554-62. PubMed ID: 26553688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac.
    Tang Y; Plikaytis BD; Preziosi MP; Borrow R
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S531-9. PubMed ID: 26553685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.
    Findlow H; Sow S; Borrow R; Tapia M; Haidara FC; Akinsola AK; Idoko OT; Diallo F; Adegbola R; Tang Y; Parulekar V; Chadha H; Mabey L; Holme D; Townsend K; Chaumont J; Laforce FM; Kulkarni PS; Marchetti E; Viviani S; Hassan-King M; Preziosi MP
    Clin Vaccine Immunol; 2011 Sep; 18(9):1492-6. PubMed ID: 21752951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
    Tapia MD; Findlow H; Idoko OT; Preziosi MP; Kulkarni PS; Enwere GC; Elie C; Parulekar V; Sow SO; Haidara FC; Diallo F; Doumbia M; Akinsola AK; Adegbola RA; Kampmann B; Chaumont J; Martellet L; Marchetti E; Viviani S; Tang Y; Plikaytis BD; LaForce FM; Carlone G; Borrow R
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S514-20. PubMed ID: 26553683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.
    Idoko OT; Okolo SN; Plikaytis B; Akinsola A; Viviani S; Borrow R; Carlone G; Findlow H; Elie C; Kulkarni PS; Preziosi MP; Ota M; Kampmann B
    Vaccine; 2014 Jul; 32(33):4220-7. PubMed ID: 24863486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
    Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials.
    White M; Idoko O; Sow S; Diallo A; Kampmann B; Borrow R; Trotter C
    Lancet Infect Dis; 2019 Mar; 19(3):327-336. PubMed ID: 30745277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
    Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
    Hirve S; Bavdekar A; Pandit A; Juvekar S; Patil M; Preziosi MP; Tang Y; Marchetti E; Martellet L; Findlow H; Elie C; Parulekar V; Plikaytis B; Borrow R; Carlone G; Kulkarni PS; Goel A; Suresh K; Beri S; Kapre S; Jadhav S; Preaud JM; Viviani S; LaForce FM
    Vaccine; 2012 Oct; 30(45):6456-60. PubMed ID: 22898557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.
    Holme D; Findlow H; Sow SO; Idoko OT; Preziosi MP; Carlone G; Plikaytis BD; Borrow R
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S563-9. PubMed ID: 26553689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.
    Bash MC; Lynn F; Mocca B; Borrow R; Findlow H; Hassan-King M; Preziosi MP; Idoko O; Sow S; Kulkarni P; Laforce FM
    Clin Vaccine Immunol; 2014 May; 21(5):755-61. PubMed ID: 24671551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
    Yaro S; Njanpop Lafourcade BM; Ouangraoua S; Ouoba A; Kpoda H; Findlow H; Tall H; Seanehia J; Martin C; Ouedraogo JB; Gessner B; Meda N; Borrow R; Trotter C; Mueller JE
    Clin Infect Dis; 2019 Jan; 68(3):435-443. PubMed ID: 30481265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.
    Findlow H; Plikaytis BD; Aase A; Bash MC; Chadha H; Elie C; Laher G; Martinez J; Herstad T; Newton E; Viviani S; Papaspyridis C; Kulkarni P; Wilding M; Preziosi MP; Marchetti E; Hassan-King M; La Force FM; Carlone G; Borrow R
    Clin Vaccine Immunol; 2009 Jul; 16(7):969-77. PubMed ID: 19474264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
    Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
    Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.
    Quiambao BP; Bavdekar A; Dubey AP; Jain H; Kolhe D; Bianco V; Miller JM; Van der Wielen M
    Hum Vaccin Immunother; 2017 Mar; 13(3):636-644. PubMed ID: 28152332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal vaccines and protein-energy undernutrition in children in the African meningitis belt.
    Sundaram ME; Wolfson J; Osterholm M; Sow S; Ansah PO; Diallo A; Cusick SE
    Vaccine; 2020 Dec; 38(52):8351-8356. PubMed ID: 33223309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.
    Tapia MD; Sow SO; Haidara FC; Diallo F; Doumbia M; Enwere GC; Paranjape G; Hervé J; Bouma E; Parulekar V; Martellet L; Chaumont J; Plikaytis BD; Tang Y; Kulkarni PS; Hartmann K; Preziosi MP
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S507-13. PubMed ID: 26553682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.